NAS
CGEM icon

Nykredit A/S’s Cullinan Oncology CGEM Stock Holding History

Nykredit A/S’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.3K Buy
+948
New +$14.1K ﹤0.01% 1765

Other funds holding CGEM

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Nykredit A/S's CGEM Position: Q2 2026 in Review

Nykredit A/S opened a new position in Cullinan Oncology (CGEM) in Q2 2026: 948 shares worth $17.3K. The stake represents ﹤0.01% of the portfolio and ranks #1765 among its holdings.

121 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • Nykredit A/S held 948 shares of Cullinan Oncology worth $17.3K as of Q2 2026.
  • Cullinan Oncology was a new Nykredit A/S position in Q2 2026.
  • Cullinan Oncology made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #1765 holding.
  • 121 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.